BLOOD Journal
Overview
publication venue for
- A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT 2023
- CAR-T Cell Therapy Vs. Standard of Care for B-Cell Lymphoma: A Systematic Review and Meta- Analysis of Updated Results of Clinical Trials 2023
- Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS) 2023
- Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group 2023
- CAR-T Prescriber Preferences in Adolescents and Young Adults with B-ALL 2022
- Clinical Characterization, Cancer Incidence and Long-Term Outcomes of Fanconi Anemia Patients : A Single Center Analysis of 97 Patients 2022
- Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes 2022
- Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) 2022
- Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL) 2021
- Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation 2021
- Phase 1/2 Study of Nexi-002 Autologous MultiAntigen-Specific CD8+T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma 2021
- Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine ( AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (>= 65 Years) AML Patients 2019
- Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia 2018
- Clinical Utility of Multiple-Gene Mutation Testing By Next-Generation Sequencing in Acute Myeloid Leukemia in Community Hospital Setting 2018
- Acute Promyelocytic Leukemia with FLT3/ITD and RUNX1 Mutation Presenting As Extramedullary Soft Tissue Mass 2016
- Evaluation of a Rapid and Automated Heparin-Induced Thrombocytopenia Immunoassay 2016
- First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis 2016
- Low Dose Steroids Can Alleviate Blinatumomab-Associated Toxicities without Negatively Impacting Treatment Efficacy 2015
- Thymoglobulin Does Not Impact Relapse or Survival after Matched Unrelated Transplantation for AML/MDS Compared to Matched Related Donor Transplantation without Thymoglobulin Use 2015
- CD32a antibodies induce thrombocytopenia and type II hypersensitivity reactions in FCGR2A mice. 126:2230-2238. 2015
- Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia. 125:3411-3419. 2015
- Effect of Graft and Early Posttransplantation Invariant Natural Killer T Cells on Disease Relapse Post Allogeneic Hematopoeitic Cell Transplantation 2014
- In Vitro Preactivation of PBMCs with PM-mb21-41BBL Particles Stimulates in Vivo Expansion of NK Cells Under Low IL-2 in NSG Mice 2014
- Method of Mobilization: Implication on Cell Subsets in the Graft and Immune Reconstitution Post Autologous Hematopoietic Cell Transplantation (AHCT) 2014
- Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia. 122:3440-3449. 2013
- Leukocytosis Post Engraftment Is Associated with Increased Mortality Among Adult Allogeneic Hematopoietic Cell Transplant (HCT) Reciepients 2012
- Physician's Experience and Continuity of Care May Result in Superior Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematological Malignancies with Standard Conditioning Regimens and GVHD Prophylaxis 2012
- Plasma Cell CD20 Expression After Autologous Stem Cell Transplantation in Multiple Myeloma: Primary Aberrant Expression or Receptor up-Regulation 2012
- The Impact of Continuity of Care On Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation; Improved Overall Survival in the Absence of Severe Graft Vs. Host Disease 2012
- beta(2)-Glycoprotein 1 Antibodies Directly Activate the Platelet IgG Receptor, Fc gamma RIIa, and Cause Thrombosis in FCGR2A Transgenic but Not in Wild Type Mice 2012
- Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. 119:3164-3175. 2012
- Is It Time for Arraycgh to Be the First Line Test for Detection of Chromosome Abnormalities in Hematological Disorders-Example Multiple Myeloma 2011
- Comparison of Platelet-Activating Potential of Bevacizumab plus VEGF and Aflibercept plus VEGF Complexes. 2010
- Role of Protein Disulfide Isomerase (PDI) In the Expression of Tissue Factor (TF) Procoagulant Activity on Apoptotic Myeloblasts 2010
- Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. 114:4998-5002. 2009
- Nephrotic Syndrome After Allogeneic Hematopoietic Cell Transplantation: Incidence and Outcomes 2009
- Bevacizumab Immune Complexes Induce Thrombocytopenia and Thrombosis in Mice Transgenic for Human IgG Receptor FcYRHa 2008
- Mechanism of Thrombocytopenia Induced by Anti-CD40 Ligand Immune Complexes and the Prevalence of CD40 Ligand Autoantibodies in Patients with Thrombotic Autoimmune Disorders. 2008
- Microparticle-Associated Tissue Factor: A Molecular Link Between Coagulation Activation, Inflammation and Disease Progression in Early-Stage Prostate Cancer? 2008
- High-dose calcitriol modulates the expression and activity of tissue factor and thrombomodulin in tumor cells. 2007
- Role of the IL-6 pathway in multiple myeloma cell growth and its implications in target gene hypermethylation 2007
- Blood-borne, but not endothelial CD40 promotes experimental lung metastasis. 2006
- Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B study 10301. 2006
- Functional and antigenic detection of intravascular tissue factor (TF). 2006
- Hypercoagulability in ovarian cancer revisited: A prospective analysis of coagulation and platelet activation markers. 2006
- Mechanisms of platelet activation by antithymocyte globulin (ATG). 2006
- Platelet activation by a humanized monoclonal CD40 ligand (CD40L) antibody. 2006
- Prospective evaluation of laboratory tests for the diagnosis of heparin-induced thrombocytopenia. 2006
- Targeting angiogenesis in cancer: Bevacizumab-induced platelet activation as a possible cause for unexpected arterial thromboembolic events in clinical trials. 2006
- Tissue factor-bearing microparticles derived from tumor cells: Impact on coagulation activation. 2006
- Experimental metastasis, tumor cell-induced coagulopathy and primary tumor growth in mice with hemophilia A 2005
- Plasma tissue factor (TF) antigen, cellular microparticles and markers of coagulation and platelet activation in localized prostate cancer 2005
- Prevalence of heparin antibodies in ICU patients (The HAICU study). 2005
- Comparison of clinical outcomes in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibitors. 2004
- Frequency of heparin-platelet factor 4 antibodies among patients with acute coronary syndromes presenting to the emergency department. 2004
- Functional consequences of cellular interactions with Heparin-PF4 antibodies in heparin-induced thrombocytopenia. 2004
- Genetic evidence that CD154 (CD40 ligand) plays a pathophysiologic role in the systemic coagulopathy associated with murine models of experimental metastasis and endotoxemia. 2004
- Successful use of bivalirudin in the treatment of patients suspected, or at risk of, heparin-induced thrombocytopenia. 2004
- The CD40/CD40 ligand (CD40L) pathway plays a role in primary hemostasis and platelet function 2004
- The relationship between systemic anticoagulation during cardiac surgery and heparin platelet factor 4 antibody formation. 2004
- Activated protein C inhibits tumor cell-induced coagulation activation in vivo and suppresses experimental lung metastasis. 2003
- An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): Role of tissue factor (TF) regulation by calcium ionophore, chemotherapeutic agents and TNF-alpha. 2003
- Bivalirudin and other direct thrombin inhibitors modulate platelet activation by thrombin and factor Xa: Clinico-pharmacologic implications for the management of HIT. 2003
- Bivalirudin, a direct thrombin inhibitor, is a safe and effective treatment for heparin-induced thrombocytopenia. 2003
- Bovine heparin generates significantly more functional heparin-PF4 antibodies of the IgG subtype than porcine heparin following cardiac surgery. 2003
- Characterization of HIT-associated heparin-PF4 antibodies in Asian-Indians: Relevance to inflammatory markers. 2003
- Direct thrombin inhibitor argatroban is capable of generating nitric oxide: Hematopharmacologic implications. 2003
- Effect of functional Heparin-PF4 antibodies from patients with heparin-induced thrombocytopenia on blood coagulation assessed by thrombelastography. 2003
- Frequency of heparin-platelet factor 4 antibodies in patients presenting to the Emergency Department with symptoms of thrombosis. 2003
- Functional heparin-PF4 antibodies from patients with heparin-induced thrombocytopenia (HIT) cause platelet-monocyte aggregation: Implications for the pathogenesis of HIT. 2003
- Investigations on the generation and functionality of PI-88 induced HIT-associated antibody subtypes in patients with malignant disorders. 2003
- Purification and partial characterization of tissue factor from human platelets. 2003
- Recurrent deep vein thrombosis (DVT) in a recipient after orthotopic liver transplantation (LTX) from a donor homozygous for the factor V Leiden mutation. 2003
- Effect of reagent choice on the APTT response to argatroban. 2002
- Frequency of heparin-platelet factor 4 antibodies in patients presenting to the emergency room with symptoms of thrombosis. 2002
- Platelet derived vascular endothelial growth factor-165 enhances tissue factor expression and procoagulant activity on tumor cells. 2002
- Platelet microparticles from healthy donors contain tissue factor. 2002
- Platelet microparticles upregulate TF and VEGF in endothelial and melanoma cells in a CD40 ligand-dependent manner: Possible role in angiogenesis and metastasis. 2002
- Trends in incidence and diagnosis of heparin-induced thrombocytopenia at a tertiary medical center: Implications for patient care. 2002
- Comparative effects of bovine and porcine heparin on heparin antibody formation following cardiovascular surgery. 2001
- Hemoglobin induces the release of vascular endothelial growth factor from human malignant cells. 2001
- Purification and partial characterization of multiple Isoforms of vascular endothelial growth factor from human platelets. 2001
- TFPI carboxy-terminal peptide exhibits anticoagulant activity and suppresses proliferation of melanoma and endothelial cells. 2001
- The oral GpIIb/IIIa antagonist (XV454) inhibits tumor cell-induced platelet aggregation in vivo and suppresses experimental lung metastasis. 2001
- The presence and release of tissue factor from human platelets. 2001
- CD40 ligand (CD40L) from activated platelets induces tissue factor expression in monocytes in vitro. 2000
- Heparin antibody formation and heparin-induced thrombocytopenia following cardiovascular surgery. 2000
- Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. 2000
- Activated platelets and TNF alpha induce tissue factor (TF) expression on A375 human melanoma cells. 1999
- Clinical experience with the Platelet Function Analyzer (PFA)-100(R). 1999
- Enhancement of tissue factor procoagulant activity by binding to hemoglobin. 1999
- Hemoglobin upregulates tissue factor expression on human malignant cells. 1999
- Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. 1998
- Comparison of the platelet function analyzer (PFA)-100 (R) and template bleeding time in clinical practice. 1998
- Mechanism of soluble fibrin augmentation of platelet-tumor cell adherence. 1998
- Platelet binding to A375 melanoma cells releases vascular endothelial growth factor (VEGF) from platelets. 1998
- Purification and characterization of tissue factor from human melanoma cells. 1998
- Fibrin monomer increases platelet adherence to tumor cells: A possible role in metastasis? 1996
- Induction of apoptosis by concanavalin A in L1210 lymphoid leukemia, A375 malignant melanoma and J82 bladder carcinoma. 1996
- Platelet and lymphocyte co-operation controls monocyte tissue factor expression in response to LPS. 1996
- Role of immune costimulatory molecules in the induction of monocyte tissue factor by LPS. 1996
- Role of tissue factor as a cytokine receptor: B7-2 costimulatory molecule controls tissue factor expression during antigen presentation. 1996
- The effect of warfarin on fibrin deposition in a murine tumor model determined by quantitative confocal laser scanning microscopy. 1996
- Anti-tumor effects of a fluorescent oxadiazole compound on leukemia, neuroblastoma, melanoma and colon carcinoma cells 1995
- Characterization of spontaneously arising B lymphocyte cell lines from normal human bone marrow 1995
- Development of a rapid and reliable adhesion assay to study the role of cellular adhesion molecules and CD34 in CD34(+) cell migration and stromal cell interaction. 1995
- Gene transfer into primitive human hematopoietic progenitor cells using commercially available lipid transfection reagents. 1995
- Importance of platelets in expression of monocyte tissue factor antigen measured by flow cytometry in whole blood. 1995
- In vitro differentiation of immortalized mesodermal cells into hematopoietic cells. 1995
- Long-term culture and characterization of a CD34(+) cell line from normal human bone marrow. 1995
- HEPARIN ENHANCES ACTIVE SITE-DEPENDENT BINDING OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR TO ENDOTHELIAL-CELLS. 80:1486-1495. 1992
- SURREPTITIOUS INGESTION OF A LONG-ACTING VITAMIN-K ANTAGONIST RODENTICIDE, BRODIFACOUM - CLINICAL AND METABOLIC STUDIES OF 3 CASES. 76:2555-2559. 1990
- VAMPIRE BAT SALIVARY PLASMINOGEN-ACTIVATOR IS QUIESCENT IN HUMAN PLASMA IN THE ABSENCE OF FIBRIN UNLIKE HUMAN TISSUE PLASMINOGEN-ACTIVATOR. 76:2560-2564. 1990
- THE PHARMACOKINETICS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN THE RABBIT. 76:1514-1520. 1990
- GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR INDUCES THE EXPRESSION OF THE CD11B SURFACE-ADHESION MOLECULE ON HUMAN-GRANULOCYTES INVIVO. 72:691-697. 1988
Research
category
- HEMATOLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 0006-4971
Electronic International Standard Serial Number (EISSN)
- 1528-0020
Other
journal abbreviation
- BLOOD